AR053895A1 - Aminopirimidinas como moduladores de quinasas - Google Patents
Aminopirimidinas como moduladores de quinasasInfo
- Publication number
- AR053895A1 AR053895A1 ARP060102426A ARP060102426A AR053895A1 AR 053895 A1 AR053895 A1 AR 053895A1 AR P060102426 A ARP060102426 A AR P060102426A AR P060102426 A ARP060102426 A AR P060102426A AR 053895 A1 AR053895 A1 AR 053895A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- heteroaryl
- alkylamino
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) y N-oxidos, sales aceptables para uso farmacéutico, solvatos, isomeros geométricos e isomeros estereoquímicos del mismo, donde: q es 0, 1 o 2; p es 0 o 1; Q es NH, N(alquilo), O, o un enlace directo; Z es NH, N(alquilo), o CH2; B es fenilo, heteroarilo, o un heteroarilo benzo-fusionado de 1 a 9 miembros; R1 es como se muestra en el resto de formula (2), donde n es 1, 2, 3 o 4; Ra es H, alcoxi, fenoxi, fenilo, heteroarilo sustituido en forma opcional con R5, hidroxilo, amino, alquilamino, dialquilamino, oxazolidinonilo sustituido en forma opcional con R5, pirrolidinonilo sustituido en forma opcional con R5, piperidinonilo sustituido en forma opcional con R5, heterodionilo cíclico sustituido en forma opcional con R5, heterociclilo sustituido en forma opcional con R5, -COORy, -CONRwRx, -N(Rw)CON(Ry)(Rx), -N(Ry)CON(Rw)(Rx), -N(Rw)C(O)ORx, -N(Rw)CORy, -SRy, -SORy, -SO2Ry, -NRwSO2Ry, -NRwSO2Rx, -SO3Ry, -OSO2NRwRx o -SO2NRwRx; R5 es 1, 2 o 3 sustituyentes seleccionados en forma independiente de halogeno, ciano, trifluorometilo, amino, hidroxilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)N(alquilo)2, -alquil C1-4-OH o alquilamino; Rw y Rx se seleccionan en forma independiente de H, alquilo, alquenilo, aralquilo, o heteroaralquilo, o Rw y Rx pueden tomarse juntos en forma opcional para formar un anillo de 5 a 7 miembros, que contiene opcionalmente un resto con heteroátomo seleccionado de O, NH, N(alquilo), SO2, SO, o S; Ry se selecciona de H, alquilo, alquenilo, cicloalquilo, fenilo, aralquilo, heteroaralquilo, o heteroarilo; y R3 es uno o más sustituyentes seleccionados en forma independiente de: H, alquilo, alcoxi, halogeno, alcoxiéter, hidroxilo, tio, nitro, cicloalquilo sustituido en forma opcional con R4, heteroarilo sustituido en forma opcional con R4, alquilamino, heterociclilo sustituido en forma opcional con R4, -O(cicloalquilo), pirrolidinonilo sustituido en forma opcional con R4, fenoxi sustituido en forma opcional con R4, -CN, -OCHF2, -OCF3, -CF3, alquilo halogenado, heteroariloxi sustituido en forma opcional con R4, dialquilamino, -NHSO2alquilo, tioalquilo o -SO2alquilo; donde R4 se selecciona en forma independiente de halogeno, ciano, trifluorometilo, amino, hidroxilo, alcoxi, -C(O)alquilo, -CO2alquilo, -SO2alquilo, -C(O)N(alquilo)2, alquilo o alquilamino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68971705P | 2005-06-10 | 2005-06-10 | |
| US75108405P | 2005-12-16 | 2005-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053895A1 true AR053895A1 (es) | 2007-05-23 |
Family
ID=36929309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102426A AR053895A1 (es) | 2005-06-10 | 2006-06-09 | Aminopirimidinas como moduladores de quinasas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060281764A1 (es) |
| EP (1) | EP1896029A1 (es) |
| JP (1) | JP2008543760A (es) |
| KR (1) | KR20080028911A (es) |
| AR (1) | AR053895A1 (es) |
| AU (1) | AU2006258054A1 (es) |
| BR (1) | BRPI0611963A2 (es) |
| CA (1) | CA2611470A1 (es) |
| EA (1) | EA200800015A1 (es) |
| EC (1) | ECSP077991A (es) |
| GT (1) | GT200600248A (es) |
| IL (1) | IL187693A0 (es) |
| NI (1) | NI200700316A (es) |
| NO (1) | NO20080163L (es) |
| PE (1) | PE20070076A1 (es) |
| TW (1) | TW200718693A (es) |
| WO (1) | WO2006135644A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009507896A (ja) * | 2005-09-13 | 2009-02-26 | パラウ・フアルマ・ソシエダツド・アノニマ | ヒスタミンｈ４受容体活性の調節剤としての２−アミノピリミジン誘導体 |
| CN101511359B (zh) | 2006-09-08 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 苯并三唑激酶调节剂 |
| US20080076770A1 (en) * | 2006-09-25 | 2008-03-27 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| EP2136809A4 (en) * | 2007-03-20 | 2012-01-04 | Curis Inc | INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT |
| WO2010054185A1 (en) * | 2008-11-06 | 2010-05-14 | Ambit Biosciences Corporation | Phosphorylated fms-related tyrosine kinase 3 biomarker assay |
| US20110230497A1 (en) * | 2008-11-07 | 2011-09-22 | H. Lundbeck A/S | Biologically active amides |
| ES2891543T3 (es) | 2009-09-04 | 2022-01-28 | Biogen Ma Inc | Inhibidores de la tirosina quinasa de Bruton |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| MX2019000884A (es) | 2016-07-21 | 2019-09-04 | Biogen Ma Inc | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. |
| EP3519385B1 (en) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
| UA127346C2 (uk) * | 2017-03-16 | 2023-07-26 | Крінетікс Фармасьютікалс, Інк. | Модулятори соматостатину та їх застосування |
| US11608335B2 (en) | 2018-02-12 | 2023-03-21 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| TWI852944B (zh) | 2018-09-18 | 2024-08-21 | 美商克林提克斯醫藥股份有限公司 | 生長抑制素(somatostatin)調節劑及其用途 |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| MX2023009603A (es) | 2021-02-17 | 2023-08-24 | Crinetics Pharmaceuticals Inc | Formas cristalinas de un modulador de somatostatina. |
| WO2024129614A1 (en) | 2022-12-13 | 2024-06-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383546A1 (en) * | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| WO2003026665A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
-
2006
- 2006-06-06 US US11/422,362 patent/US20060281764A1/en not_active Abandoned
- 2006-06-07 NI NI200700316A patent/NI200700316A/es unknown
- 2006-06-07 WO PCT/US2006/022165 patent/WO2006135644A1/en active Application Filing
- 2006-06-07 BR BRPI0611963-8A patent/BRPI0611963A2/pt not_active Application Discontinuation
- 2006-06-07 CA CA002611470A patent/CA2611470A1/en not_active Abandoned
- 2006-06-07 JP JP2008515885A patent/JP2008543760A/ja not_active Withdrawn
- 2006-06-07 PE PE2006000625A patent/PE20070076A1/es not_active Application Discontinuation
- 2006-06-07 AU AU2006258054A patent/AU2006258054A1/en not_active Abandoned
- 2006-06-07 EA EA200800015A patent/EA200800015A1/ru unknown
- 2006-06-07 KR KR1020087000399A patent/KR20080028911A/ko not_active Application Discontinuation
- 2006-06-07 EP EP06772456A patent/EP1896029A1/en not_active Withdrawn
- 2006-06-08 GT GT200600248A patent/GT200600248A/es unknown
- 2006-06-09 TW TW095120473A patent/TW200718693A/zh unknown
- 2006-06-09 AR ARP060102426A patent/AR053895A1/es not_active Application Discontinuation
-
2007
- 2007-11-27 IL IL187693A patent/IL187693A0/en unknown
- 2007-12-10 EC EC2007007991A patent/ECSP077991A/es unknown
-
2008
- 2008-01-09 NO NO20080163A patent/NO20080163L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NI200700316A (es) | 2009-03-03 |
| ECSP077991A (es) | 2008-01-23 |
| KR20080028911A (ko) | 2008-04-02 |
| JP2008543760A (ja) | 2008-12-04 |
| IL187693A0 (en) | 2008-08-07 |
| NO20080163L (no) | 2008-03-07 |
| TW200718693A (en) | 2007-05-16 |
| US20060281764A1 (en) | 2006-12-14 |
| GT200600248A (es) | 2007-03-14 |
| BRPI0611963A2 (pt) | 2010-10-13 |
| PE20070076A1 (es) | 2007-02-09 |
| CA2611470A1 (en) | 2006-12-21 |
| EP1896029A1 (en) | 2008-03-12 |
| AU2006258054A1 (en) | 2006-12-21 |
| EA200800015A1 (ru) | 2008-06-30 |
| WO2006135644A1 (en) | 2006-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053895A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| AR054388A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| AR054386A1 (es) | Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina | |
| AR057063A1 (es) | Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica | |
| AR055144A1 (es) | Inhibidor de secrecion acida | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20060622A1 (es) | Derivados de pirimidina como inhibidores de fak | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR106778A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo | |
| PE20141691A1 (es) | Compuestos con actividad nematicida | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| PE20121047A1 (es) | Derivados de tiazolilpiperidina como fungicidas | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| EA201990279A1 (ru) | Гербицидные композиции, содержащие фенилпиримидины | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| EA201100009A1 (ru) | Соединения 1,2-бензизотиазола, полезные для борьбы с животными-вредителями | |
| AR103397A1 (es) | Oxoborazoles microbicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |